Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.

Brain : a journal of neurology - 1 Jul 2016

Masellis Mario, Collinson Shannon, Freeman Natalie, Tampakeras Maria, Levy Joseph, Tchelet Amir, Eyal Eli, Berkovich Elijahu, Eliaz Rom E, Abler Victor, Grossman Iris, Fitzer-Attas Cheryl, Tiwari Arun, Hayden Michael R, Kennedy James L, Lang Anthony E, Knight Jo

Abstract excerpt

The treatment of early Parkinson's disease with dopaminergic agents remains the mainstay of symptomatic therapy for this incurable neurodegenerative disorder. However, clinical responses to dopaminergic drugs vary substantially from person to person due to individual-, drug- and disease-related factors that may in part be genetically determined. Using clinical data and DNA samples ascertained through the largest...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Follow-Up Studies
Share to Indans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Outcome Assessment, Health Care

Share to Parkinson Disease

Share to Pharmacogenomic Testing

Share to Receptors, Dopamine D2

Share to Severity of Illness Index

Share to Tandem Repeat Sequences

Source

Identifiers

PMID: 27190009
DOI: 10.1093/brain/aww109

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.PMID 27190009Read ↗

Parkinson’s Disease Pharmacogenomics: New Findings and PerspectivesSemantic proximity Read ↗

Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s DiseaseSemantic proximity Read ↗

Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic StudiesSemantic proximity Read ↗

A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?Semantic proximity Read ↗

Anti-Parkinson's disease drugs and pharmacogenetic considerationsSemantic proximity Read ↗

Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome.Semantic proximity Read ↗

Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.Semantic proximity Read ↗

Finding drug targeting mechanisms with genetic evidence for Parkinson’s diseaseSemantic proximity Read ↗

The Role of Single Nucleotide Polymorphisms of Monoamine Oxidase B, Dopamine D2 Receptor, and DOPA Decarboxylase Receptors Among Patients Treated for Parkinson's Disease.Semantic proximity Read ↗

Polymorphisms in candidate genes: implications for the current treatment of Parkinson's disease.Semantic proximity Read ↗

Drug Repurposing for Parkinson’s Disease: A Large-Scale Multi-Cohort StudySemantic proximity Read ↗

Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.